CEO of BioCardia Accumulates 5,000 Shares Amid 55% Stock Drop, Signals Confidence in Turnaround Efforts

Insider Buying Continues Amid a Tumultuous Market

Altman Peter, the President and CEO of BioCardia Inc., added 5,000 shares of the company’s common stock on February 4, 2026, paying $1.13 per share. The purchase comes on the heels of a modest $1.09 market price and a slight 0.06 % decline from the previous close. Though the transaction size is modest relative to the company’s market cap of roughly $12 million, the cumulative pattern of purchases by Altman over the past year paints a picture of confidence that is worth noting by investors watching a stock that has slipped more than 55 % from its 52‑week high.

Implications for Investors and the Company’s Outlook

The CEO’s buying spree has intensified since the first quarter of 2025, when Altman began accumulating shares in large blocks—most notably a 106,588‑share purchase in December 2025 at $1.37 each. By the time of the February 4 transaction, his holdings had risen to 273,866 shares, an increase of over 70 % in a year. While insider purchases are generally viewed positively, the broader context—BioCardia’s negative earnings, a P/E ratio of –2.5 and a sharp decline in share price—suggests that the CEO’s confidence may be rooted more in the potential for a turnaround than in current profitability.

For investors, the message is twofold. First, insider activity can signal management’s belief in the company’s long‑term prospects, which may justify a higher valuation than the market currently reflects. Second, the lack of any recent clinical milestones (the last update was the CardiAMP HF trial in February 2026) means that any upside is contingent on future data releases or regulatory approvals. If BioCardia can secure a breakthrough product or secure a meaningful partnership, the stock could rally; if not, the current downward trend may continue.

Altman Peter: A Profile of Consistent Confidence

Altman’s purchase history shows a pattern of incremental buying, often in response to stock price dips or new clinical information. The CEO’s first large buy in December 2025 (106,588 shares) was followed by a smaller 400‑share purchase in August 2025 at $1.75—an outlier price that suggests a strategic entry point. Subsequent purchases were typically in the $1.30–$1.40 range, indicating a willingness to pay slightly above the market price when the share count was high. Importantly, Altman has never sold any shares, reinforcing a long‑term investment horizon. This disciplined buying pattern signals that the CEO sees value in the company that is not yet fully priced into the market.

What This Means for BioCardia’s Future

The convergence of insider buying, a negative earnings trajectory, and a stagnant clinical pipeline creates a complex scenario for investors. While Altman’s actions could be interpreted as a vote of confidence, the absence of recent breakthrough data means that BioCardia’s stock remains vulnerable to market sentiment and macro‑economic pressures. Investors should watch for upcoming data releases, potential partnership announcements, and any shifts in the company’s cash position. In the meantime, Altman’s continued accumulation may provide a stabilizing influence, but only time will determine whether the CEO’s confidence translates into shareholder value.